30 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Is a Beat in the Cards for Mallinckrodt (MNK) in Q3 Earnings? http://www.zacks.com/stock/news/598368/is-a-beat-in-the-cards-for-mallinckrodt-mnk-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-598368 Nov 01, 2019 - Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q3 results.
WIll Allergan (AGN) Beat Estimates This Earnings Season? http://www.zacks.com/stock/news/598369/will-allergan-agn-beat-estimates-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-598369 Nov 01, 2019 - Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q3 as loss of exclusivity of several products hurts sales.
Allergan (AGN) Q3 Earnings Meet Estimates http://www.zacks.com/stock/news/604109/allergan-agn-q3-earnings-meet-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-604109 Nov 05, 2019 - Allergan (AGN) delivered earnings and revenue surprises of 0.00% and 4.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View http://www.zacks.com/stock/news/604652/allergan-agn-meets-q3-earnings-estimates-ups-19-sales-view?cid=CS-ZC-FT-analyst_blog|earnings_article-604652 Nov 05, 2019 - Botox, Juveederm fillers, Vraylar drive Allergan's (AGN) third-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
3 Stocks for Value Investors to Buy as Market Reaches New High http://www.zacks.com/stock/news/644023/3-stocks-for-value-investors-to-buy-as-market-reaches-new-high?cid=CS-ZC-FT-stocks_in_the_news|investment_ideas-644023 Nov 27, 2019 - The stock market closed at a record high today as the DJIA rose over 42 points and the S&P 500 gained 0.4%.
Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs http://www.zacks.com/stock/news/505264/pharma-stock-roundup-agns-opioid-settlement-line-extension-nod-in-eu-for-mrk-jnj-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-505264 Sep 06, 2019 - Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
Coalition urges FTC block to ABBV-AGN deal https://seekingalpha.com/news/3499276-coalition-urges-ftc-block-abbv-agn-deal?source=feed_news_all Sep 13, 2019 - Consumer groups and unions want the FTC to block AbbVie's (ABBV +0.4%) $63B acquisition of Allergan (AGN), according to a STAT report.The coalition says the increasingly concentrated nature of the hea
Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment http://www.zacks.com/stock/news/516990/ardelyx-gets-fda-approval-for-ibsrela-as-ibs-c-treatment?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-516990 Sep 13, 2019 - Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.
IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA http://www.zacks.com/stock/news/539102/intelgenx-igxt-resubmits-nda-for-migraine-candidate-to-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-539102 Sep 27, 2019 - IntelGenx Corp. (IGXT) resubmits NDA for Rizaport VersaFilm for the treatment of acute migraines to the FDA.
Wet AMD Space in Focus: New Drug Approvals & Key Advancements http://www.zacks.com/stock/news/557772/wet-amd-space-in-focus-new-drug-approvals-key-advancements?cid=CS-ZC-FT-analyst_blog|industry_focus-557772 Oct 10, 2019 - The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.

Pages: 123

<Page 2